DRUG BRIGHT MINDS BIOSCIENCES INC. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1827401 · Reporting currency CAD · Fiscal year ends 09/30
Financial factors as of 2024-09-30 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-09-30 | FY2023*2023-09-30 | FY2022*2022-09-30 | FY2021*2021-09-30 | FY2020*2020-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 1.18M | 5.00M | 12.18M | 6.31M | 354,852 |
| SG&A expense | 264,009 | 278,809 | 478,248 | 197,125 | 637 |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | -2.80M | -7.37M | -14.96M | -8.65M | -480,377 |
| EPS (basic) | -0.65 | -1.98 | -6.06 | -4.82 | -0.13 |
| EPS (diluted) | -0.65 | -1.98 | -6.06 | -4.82 | -0.13 |
| Weighted avg. shares (diluted) | 4.31M | 3.72M | 2.47M | 1.79M | — |
| Balance sheet | |||||
| Cash & equivalents | 5.72M | 6.75M | 11.63M | 19.76M | 799,929 |
| Current assets | 5.99M | 6.81M | 11.95M | 20.04M | 878,216 |
| Total assets | 6.10M | 6.88M | 12.09M | 20.04M | 880,216 |
| Current liabilities | 528,683 | 280,856 | 1.47M | 638,573 | — |
| Total liabilities | 568,259 | 280,856 | 1.54M | 638,573 | 150,923 |
| Shareholders' equity | 5.54M | 6.60M | 10.54M | 19.40M | 729,293 |
| Cash flow statement | |||||
| Operating cash flow | -1.85M | -7.02M | -13.59M | -7.32M | -288,392 |
| Financing cash flow | 810,572 | 2.19M | 5.20M | 26.06M | 1.01M |
| Depreciation & amortization | 73,357 | 72,450 | 6,037 | 0 | 0 |
| Stock-based compensation | 839,771 | 1.15M | 875,056 | 880,615 | 161,300 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.